# Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS

> **NCT04057898** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MediciNova** · enrollment: 234 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** MN-166
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT04057898
- **Lead sponsor:** MediciNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-28
- **Primary completion:** 2027-04
- **Final completion:** 2028-04
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04057898

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04057898, "Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04057898. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*